Featured Research

from universities, journals, and other organizations

"Silent" HIV Infection Lasts A Lifetime -- Hopkins Physicians Urge Patients To Keep Taking Anti-HIV Medication

Date:
April 29, 1999
Source:
Johns Hopkins Medical Institutions
Summary:
In 1995, researchers at Johns Hopkins discovered HIV (human immunodeficiency virus) evades anti-viral drugs by hiding in the immune system, infecting certain white blood cells, called T cells, and then going to sleep, or turning off. In the May Nature Medicine, the same team reports this silent infection persists for a lifetime.

In 1995, researchers at Johns Hopkins discovered HIV (human immunodeficiency virus) evades anti-viral drugs by hiding in the immune system, infecting certain white blood cells, called T cells, and then going to sleep, or turning off. In the May Nature Medicine, the same team reports this silent infection persists for a lifetime.

"This doesn't mean a cure for HIV is impossible, but it is an obstacle," says Robert Siliciano, M.D., Ph.D., senior author on the report. "And it emphasizes that patients need to stay on their medication, possibly for the rest of their lives."

However, not all news from the study was bleak. The study patients, who kept to their strict drug regimens under supervision from physicians at the Johns Hopkins Moore HIV Clinic, all had undetectable levels of HIV in their blood and no signs of AIDS (acquired immune deficiency syndrome).

"The good news is that patients who comply with their therapy are able to keep the virus suppressed for long periods," says Joel Gallant, M.D., who directs the Moore Clinic. "We have assumed that therapy for HIV patients would have to be long-term or even lifelong. This study suggests that is still the case. But the study also suggests that HIV-infected patients can still live long, healthy lives without symptoms, provided they are rigorous about taking their medications." When taken as prescribed, combination therapy (the so-called "drug cocktails") of older anti-HIV drugs like AZT and newer protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs), reduces the amount of circulating virus to undetectable levels in most patients. The immune system remains relatively healthy and the collection of diseases that signal AIDS is staved off.

But the latent form of HIV can wait out even decades of anti-HIV therapy. First, it integrates its genetic code into the DNA of dormant, or resting, T cells. While the cells are in their resting phase, the HIV genes inside them remain switched off a silent infection. When the dormant cells are reactivated, say by a simple infection like the flu, the HIV genes reemerge, co-opting the cell machinery to make millions of copies of the virus.

Anti-HIV medication suppresses this flood of virus. But without medication to stop it, the virus can replicate out of control, eventually causing AIDS.

"We've seen patients without detectable virus in their blood come off their medication, and within a few weeks or months they experience a rebound, with high levels of virus in their blood," says Gallant. "Now we know that this reservoir of dormant T cells is responsible."

To measure how long the reservoir survives, the team followed 34 patients for two years, periodically drawing blood samples. Using a sophisticated cell-sorting technique developed at Hopkins, they siphoned off the dormant T cells that carried HIV genes and counted them. They found the number of silently infected cells remained stable, or declined very little. A statistical projection showed the reservoir lasting 60 years or more.

Siliciano added that because so few T cells only one in one million harbor the silent infection, they are impossible to detect without extremely precise methods. In the Nature Medicine article the team reports finding the infected T cells in 32 of 34 patients. Since writing the article, they have found silently infected cells in the other two patients.

Diana Finzi, a graduate student in Siliciano's lab, is lead author on the paper and did much of the work isolating the dormant T cells. Researchers from Harvard University, Cornell University, and the National Institute of Allergy and Infectious Diseases contributed to the study. The work was funded by the National Institute of Allergy and Infectious Diseases.

###

Relevant Web sites:

Hopkins AIDS Service: http://www.hopkins-aids.edu/

Siliciano lab: http://www.med.jhu.edu/bcmb/faculty/siliciano.html


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. ""Silent" HIV Infection Lasts A Lifetime -- Hopkins Physicians Urge Patients To Keep Taking Anti-HIV Medication." ScienceDaily. ScienceDaily, 29 April 1999. <www.sciencedaily.com/releases/1999/04/990429055219.htm>.
Johns Hopkins Medical Institutions. (1999, April 29). "Silent" HIV Infection Lasts A Lifetime -- Hopkins Physicians Urge Patients To Keep Taking Anti-HIV Medication. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/1999/04/990429055219.htm
Johns Hopkins Medical Institutions. ""Silent" HIV Infection Lasts A Lifetime -- Hopkins Physicians Urge Patients To Keep Taking Anti-HIV Medication." ScienceDaily. www.sciencedaily.com/releases/1999/04/990429055219.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins